HAEM5:Langerhans cell histiocytosis: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Bailey.Glen (talk | contribs) Created page with "{{DISPLAYTITLE:Langerhans cell histiocytosis}} Haematolymphoid Tumours (5th ed.) {{Under Construction}} <blockquote class='blockedit'>{{Box-round..." |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11- | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Langerhans Cell Histiocytosis]]. | ||
}}</blockquote> | }}</blockquote> | ||
==Primary Author(s)*== | ==Primary Author(s)*== | ||
| Line 12: | Line 12: | ||
__TOC__ | __TOC__ | ||
==Cancer Category/Type== | ==Cancer Category / Type== | ||
Histiocytic and dendritic cell neoplasms | Histiocytic and dendritic cell neoplasms | ||
| Line 184: | Line 184: | ||
</blockquote> | </blockquote> | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain / Loss / LOH== | ||
Recurrent regional losses, gains, or regions with loss of heterozygosity have not been identified in the context of Langerhans cell histiocytosis. | Recurrent regional losses, gains, or regions with loss of heterozygosity have not been identified in the context of Langerhans cell histiocytosis. | ||
| Line 223: | Line 223: | ||
| | | | ||
|} | |} | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV / INDEL)== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span> | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span> | ||
| Line 257: | Line 257: | ||
<blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the previous version of the page. Please incorporate above.}} | <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV / INDEL)|The content below was from the previous version of the page. Please incorporate above.}} | ||
More than half of LCH cases display a ''BRAF V600E'' variant. Approximately 25% of LCH cases have an associated somatic MAP2K1 mutation in parallel with a germline BRAF variant <ref name=":0" />. | More than half of LCH cases display a ''BRAF V600E'' variant. Approximately 25% of LCH cases have an associated somatic MAP2K1 mutation in parallel with a germline BRAF variant <ref name=":0" />. | ||
| Line 327: | Line 327: | ||
<nowiki>*</nowiki>''Citation of this Page'': “Langerhans cell histiocytosis”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Langerhans_cell_histiocytosis</nowiki>.[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases L]] | <nowiki>*</nowiki>''Citation of this Page'': “Langerhans cell histiocytosis”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Langerhans_cell_histiocytosis</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases L]] | |||